Addressing the 'hypoxia paradox' in severe COVID-19: literature review and report of four cases treated with erythropoietin analogues.

MLA

Begemann, Martin, et al. “Addressing the ‘Hypoxia Paradox’ in Severe COVID-19: Literature Review and Report of Four Cases Treated with Erythropoietin Analogues.” Molecular Medicine, vol. 27, no. 1, Sept. 2021, pp. 1–11. EBSCOhost, https://doi.org/10.1186/s10020-021-00381-5.

APA

Begemann, M., Gross, O., Wincewicz, D., Hardeland, R., Daguano Gastaldi, V., Vieta, E., Weissenborn, K., Miskowiak, K. W., Moerer, O., & Ehrenreich, H. (2021). Addressing the “hypoxia paradox” in severe COVID-19: literature review and report of four cases treated with erythropoietin analogues. Molecular Medicine, 27(1), 1–11. https://doi.org/10.1186/s10020-021-00381-5

Chicago

Begemann, Martin, Oliver Gross, Dominik Wincewicz, Rüdiger Hardeland, Vinicius Daguano Gastaldi, Eduard Vieta, Karin Weissenborn, Kamilla W. Miskowiak, Onnen Moerer, and Hannelore Ehrenreich. 2021. “Addressing the ‘Hypoxia Paradox’ in Severe COVID-19: Literature Review and Report of Four Cases Treated with Erythropoietin Analogues.” Molecular Medicine 27 (1): 1–11. doi:10.1186/s10020-021-00381-5.